Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.75
+1.7%
$1.83
$1.41
$4.34
$74.64M0.16724,283 shs522,387 shs
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
$22.00
+7.3%
$14.67
$7.50
$19.22
$295.42M0.0174,040 shs25,340 shs
Organogenesis stock logo
ORGO
Organogenesis
$2.43
$2.46
$2.04
$7.08
$312.68M1.321.15 million shs2.84 million shs
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$3.92
-0.8%
$4.47
$3.82
$9.62
$281.14M0.91552,885 shs1.99 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-1.15%-8.51%-5.49%-6.01%-11.79%
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
+2.04%+46.85%+45.54%+16.31%+209.01%
Organogenesis stock logo
ORGO
Organogenesis
-0.41%-0.41%-8.65%+6.11%-31.36%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
-8.56%-8.56%-15.42%-25.47%-38.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.75
+1.7%
$1.83
$1.41
$4.34
$74.64M0.16724,283 shs522,387 shs
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
$22.00
+7.3%
$14.67
$7.50
$19.22
$295.42M0.0174,040 shs25,340 shs
Organogenesis stock logo
ORGO
Organogenesis
$2.43
$2.46
$2.04
$7.08
$312.68M1.321.15 million shs2.84 million shs
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$3.92
-0.8%
$4.47
$3.82
$9.62
$281.14M0.91552,885 shs1.99 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-1.15%-8.51%-5.49%-6.01%-11.79%
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
+2.04%+46.85%+45.54%+16.31%+209.01%
Organogenesis stock logo
ORGO
Organogenesis
-0.41%-0.41%-8.65%+6.11%-31.36%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
-8.56%-8.56%-15.42%-25.47%-38.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.67
Moderate Buy$8.50385.71% Upside
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
0.00
N/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$5.75136.63% Upside
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest GANX, ORGO, SIGA, and JMAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/15/2026
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
UpgradeSell (D+)Hold (C-)
6/9/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
DowngradeSell (D-)Sell (E+)
5/28/2026
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
DowngradeHold (C-)Sell (D+)
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Set Price Target$3.00
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Initiated CoverageHold$3.00
5/27/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Reiterated RatingOutperform
5/12/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Reiterated RatingBuy
5/11/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeHold (C)Sell (D)
5/11/2026
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
UpgradeSell (D+)Hold (C-)
5/8/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeBuyNeutral
4/10/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Reiterated RatingSell (D-)
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$50K1,492.75N/AN/A$0.48 per share3.65
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
$512.59M0.61$0.64 per share3.77$2.36 per share1.03
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$94.57M2.97$0.30 per share12.98$2.78 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
$37.03M-$0.19N/AN/AN/A-0.84%9.63%4.76%8/6/2026 (Estimated)
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$23.28M$0.2714.52N/AN/A21.58%10.60%8.94%8/4/2026 (Estimated)

Latest GANX, ORGO, SIGA, and JMAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.13-$0.13N/A-$0.13$0.03 millionN/A
5/7/2026Q1 2026
Organogenesis stock logo
ORGO
Organogenesis
-$0.29-$0.37-$0.08-$0.44$43.26 million$37.23 million
5/7/2026Q1 2026
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A-$0.05N/A-$0.05N/A$6.24 million
3/26/2026Q4 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.14-$0.11+$0.03-$0.11$0.03 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/AN/AN/AN/AN/A

Latest GANX, ORGO, SIGA, and JMAC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/26/2026
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
special$0.604/7/20264/7/20264/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.02
4.69
4.69
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
0.05
3.53
3.16
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A
3.25
2.38

Institutional Ownership

CompanyInstitutional Ownership
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
73.18%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
55.40%

Insider Ownership

CompanyInsider Ownership
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
4.15%
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
19.27%
Organogenesis stock logo
ORGO
Organogenesis
18.80%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
2.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2042.65 million40.88 millionOptionable
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
2,02113.43 million10.84 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950128.68 million104.48 millionOptionable
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
4071.72 million69.77 millionOptionable

Recent News About These Companies

SIGA Declares Special Cash Dividend of $0.60 Per Share

New MarketBeat Followers Over Time

Media Sentiment Over Time

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.75 +0.03 (+1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.76 +0.01 (+0.86%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Maxpro Capital Acquisition stock logo

Maxpro Capital Acquisition NASDAQ:JMAC

$22.00 +1.50 (+7.32%)
As of 06/25/2026

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.43 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.42 -0.02 (-0.62%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Siga Technologies stock logo

Siga Technologies NASDAQ:SIGA

$3.92 -0.03 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$3.92 0.00 (0.00%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.